Búsqueda | Portal de Búsqueda de la BVS Ecuador

1.

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.

Janes, Matthew R; Zhang, Jingchuan; Li, Lian-Sheng; Hansen, Rasmus; Peters, Ulf; Guo, Xin; Chen, Yuching; Babbar, Anjali; Firdaus, Sarah J; Darjania, Levan; Feng, Jun; Chen, Jeffrey H; Li, Shuangwei; Li, Shisheng; Long, Yun O; Thach, Carol; Liu, Yuan; Zarieh, Ata; Ely, Tess; Kucharski, Jeff M; Kessler, Linda V; Wu, Tao; Yu, Ke; Wang, Yi; Yao, Yvonne; Deng, Xiaohu; Zarrinkar, Patrick P; Brehmer, Dirk; Dhanak, Dashyant; Lorenzi, Matthew V; Hu-Lowe, Dana; Patricelli, Matthew P; Ren, Pingda; Liu, Yi.

Cell ; 172(3): 578-589.e17, 2018 01 25.

Artículo en Inglés | MEDLINE | ID: mdl-29373830

2.

The translational landscape of mTOR signalling steers cancer initiation and metastasis.

Hsieh, Andrew C; Liu, Yi; Edlind, Merritt P; Ingolia, Nicholas T; Janes, Matthew R; Sher, Annie; Shi, Evan Y; Stumpf, Craig R; Christensen, Carly; Bonham, Michael J; Wang, Shunyou; Ren, Pingda; Martin, Michael; Jessen, Katti; Feldman, Morris E; Weissman, Jonathan S; Shokat, Kevan M; Rommel, Christian; Ruggero, Davide.

Nature ; 485(7396): 55-61, 2012 Feb 22.

Artículo en Inglés | MEDLINE | ID: mdl-22367541

3.

Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.

Lim, Sharon; Saw, Tzuen Yih; Zhang, Min; Janes, Matthew R; Nacro, Kassoum; Hill, Jeffrey; Lim, An Qi; Chang, Chia-Tien; Fruman, David A; Rizzieri, David A; Tan, Soo Yong; Fan, Hung; Chuah, Charles T H; Ong, S Tiong.

Proc Natl Acad Sci U S A ; 110(25): E2298-307, 2013 Jun 18.

Artículo en Inglés | MEDLINE | ID: mdl-23737503

4.

Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.

So, Lomon; Yea, Sung Su; Oak, Jean S; Lu, Mengrou; Manmadhan, Arun; Ke, Qiao Han; Janes, Matthew R; Kessler, Linda V; Kucharski, Jeff M; Li, Lian-Sheng; Martin, Michael B; Ren, Pingda; Jessen, Katti A; Liu, Yi; Rommel, Christian; Fruman, David A.

J Biol Chem ; 288(8): 5718-31, 2013 Feb 22.

Artículo en Inglés | MEDLINE | ID: mdl-23275335

5.

Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins.

Romero Rosales, Kimberly; Singh, Gurpreet; Wu, Kevin; Chen, Jie; Janes, Matthew R; Lilly, Michael B; Peralta, Eigen R; Siskind, Leah J; Bennett, Michael J; Fruman, David A; Edinger, Aimee L.

Biochem J ; 439(2): 299-311, 2011 Oct 15.

Artículo en Inglés | MEDLINE | ID: mdl-21767261

6.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas, Michael G; Janes, Matthew R; Scarfone, Vanessa M; Lilly, Michael B; Knight, Zachary A; Shokat, Kevan M; Fruman, David A.

J Clin Invest ; 118(9): 3038-50, 2008 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-18704194

7.

Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.

Gilardi, Mara; Wang, Zhiyong; Proietto, Marco; Chillà, Anastasia; Calleja-Valera, Juan Luis; Goto, Yusuke; Vanoni, Marco; Janes, Matthew R; Mikulski, Zbigniew; Gualberto, Antonio; Molinolo, Alfredo A; Ferrara, Napoleone; Gutkind, J Silvio; Burrows, Francis.

Mol Cancer Ther ; 19(9): 1784-1796, 2020 09.

Artículo en Inglés | MEDLINE | ID: mdl-32727882

8.

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.

Molina-Arcas, Miriam; Moore, Christopher; Rana, Sareena; van Maldegem, Febe; Mugarza, Edurne; Romero-Clavijo, Pablo; Herbert, Eleanor; Horswell, Stuart; Li, Lian-Sheng; Janes, Matthew R; Hancock, David C; Downward, Julian.

Sci Transl Med ; 11(510)2019 09 18.

Artículo en Inglés | MEDLINE | ID: mdl-31534020

9.

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.

Misale, Sandra; Fatherree, Jackson P; Cortez, Eliane; Li, Chendi; Bilton, Samantha; Timonina, Daria; Myers, David T; Lee, Dana; Gomez-Caraballo, Maria; Greenberg, Max; Nangia, Varuna; Greninger, Patricia; Egan, Regina K; McClanaghan, Joseph; Stein, Giovanna T; Murchie, Ellen; Zarrinkar, Patrick P; Janes, Matthew R; Li, Lian-Sheng; Liu, Yi; Hata, Aaron N; Benes, Cyril H.

Clin Cancer Res ; 25(2): 796-807, 2019 01 15.

Artículo en Inglés | MEDLINE | ID: mdl-30327306

10.

An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors.

Hansen, Rasmus; Firdaus, Sarah J; Li, Shuangwei; Janes, Matthew R; Zhang, Jingchuan; Liu, Yi; Zarrinkar, Patrick P.

Sci Rep ; 8(1): 14312, 2018 09 25.

Artículo en Inglés | MEDLINE | ID: mdl-30254226

11.

The reactivity-driven biochemical mechanism of covalent KRAS^G12C inhibitors.

Hansen, Rasmus; Peters, Ulf; Babbar, Anjali; Chen, Yuching; Feng, Jun; Janes, Matthew R; Li, Lian-Sheng; Ren, Pingda; Liu, Yi; Zarrinkar, Patrick P.

Nat Struct Mol Biol ; 25(6): 454-462, 2018 06.

Artículo en Inglés | MEDLINE | ID: mdl-29760531

12.

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.

Patricelli, Matthew P; Janes, Matthew R; Li, Lian-Sheng; Hansen, Rasmus; Peters, Ulf; Kessler, Linda V; Chen, Yuching; Kucharski, Jeff M; Feng, Jun; Ely, Tess; Chen, Jeffrey H; Firdaus, Sarah J; Babbar, Anjali; Ren, Pingda; Liu, Yi.

Cancer Discov ; 6(3): 316-29, 2016 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-26739882

13.

Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.

Mallya, Sharmila; Fitch, Briana A; Lee, J Scott; So, Lomon; Janes, Matthew R; Fruman, David A.

PLoS One ; 9(2): e88865, 2014.

Artículo en Inglés | MEDLINE | ID: mdl-24586420

14.

The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia.

Janes, Matthew R; Fruman, David A.

Methods Mol Biol ; 821: 251-65, 2012.

Artículo en Inglés | MEDLINE | ID: mdl-22125070

15.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas, Michael G; Janes, Matthew R; Scarfone, Vanessa M; Lilly, Michael B; Knight, Zachary A; Shokat, Kevan M; Fruman, David A.

J Clin Invest ; 127(6): 2438, 2017 06 01.

Artículo en Inglés | MEDLINE | ID: mdl-28569734

16.

B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXR.

Casey, Stephanie C; Nelson, Edward L; Turco, Gina M; Janes, Matthew R; Fruman, David A; Blumberg, Bruce.

Mol Endocrinol ; 25(6): 933-43, 2011 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-21436254

17.

Targeting TOR dependence in cancer.

Janes, Matthew R; Fruman, David A.

Oncotarget ; 1(1): 69-76, 2010 May.

Artículo en Inglés | MEDLINE | ID: mdl-20657741

18.

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Janes, Matthew R; Limon, Jose J; So, Lomon; Chen, Jing; Lim, Raymond J; Chavez, Melissa A; Vu, Collin; Lilly, Michael B; Mallya, Sharmila; Ong, S Tiong; Konopleva, Marina; Martin, Michael B; Ren, Pingda; Liu, Yi; Rommel, Christian; Fruman, David A.

Nat Med ; 16(2): 205-13, 2010 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-20072130

19.

Immune regulation by rapamycin: moving beyond T cells.

Janes, Matthew R; Fruman, David A.

Sci Signal ; 2(67): pe25, 2009 Apr 21.

Artículo en Inglés | MEDLINE | ID: mdl-19383976

20.

Next-generation flow cytometry.

Janes, Matthew R; Rommel, Christian.

Nat Biotechnol ; 29(7): 602-4, 2011 Jul 11.

Artículo en Inglés | MEDLINE | ID: mdl-21747386

Portal de Búsqueda de la BVS Ecuador

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.

The translational landscape of mTOR signalling steers cancer initiation and metastasis.

Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.

Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.

Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.

An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors.

The reactivity-driven biochemical mechanism of covalent KRAS^G12C inhibitors.

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.

Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.

The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXR.

Targeting TOR dependence in cancer.

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Immune regulation by rapamycin: moving beyond T cells.

Next-generation flow cytometry.